What is Infraredx?
Infraredx, Inc. stands at the forefront of medical technology, specializing in high-resolution intravascular imaging systems. By integrating advanced hardware such as the Clarispro HD-IVUS and the Makoto Imaging System, the firm provides clinicians with critical, real-time insights into vascular pathology. This technological edge positions Infraredx as a pivotal player in the cardiovascular care sector, where precision imaging is essential for improving patient outcomes and optimizing treatment protocols for complex vascular conditions.
How much funding has Infraredx raised?
Infraredx has raised a total of $187.9M across 9 funding rounds:
Series A
$4.4M
Series B
$2.8M
Debt
$10M
Series D
$21M
Private Equity
$24.2M
Debt
$10M
Multiple Rounds
$115.5M
Series A (2003): $4.4M with participation from Sanderling Ventures
Series B (2005): $2.8M led by Sanderling Ventures
Debt (2010): $10M supported by Undisclosed
Series D (2010): $21M featuring Sanderling Ventures
Private Equity (2011): $24.2M, investors not publicly disclosed
Debt (2011): $10M with participation from GE Capital, Healthcare Financial Services
Private Equity (2013): $25M led by Nipro Corporation
Series C (2013): $70.5M supported by Sanderling Ventures and Nipro
Debt (2013): $20M featuring GE Capital, Healthcare Financial Services
Key Investors in Infraredx
Sanderling Ventures
A pioneering investment firm founded in 1979, specializing in building new biomedical companies through early-stage financing and active management.
Nipro Corporation
A Japan-based global provider of medical products and manufacturing support with over 50 years of experience in the healthcare community.
GE Capital, Healthcare Financial Services
A financial services entity offering specialized investment advisory and capital solutions tailored to the healthcare sector.
What's next for Infraredx?
With a robust history of financial backing, Infraredx is well-positioned to scale its operational footprint and accelerate the adoption of its NIRS-IVUS technology. The current enterprise-level funding context suggests a strategic pivot toward broader market penetration and the potential expansion of its clinical research initiatives. As the company continues to refine its imaging platforms, the focus will likely shift toward integrating artificial intelligence-driven analytics to further enhance the diagnostic utility of its existing product suite, ensuring long-term value for both healthcare institutions and stakeholders.
See full Infraredx company page
